...
首页> 外文期刊>Modern Pathology >Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH
【24h】

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH

机译:通过与 PTEN FISH进行比较,对临床级前列腺癌PTEN免疫组织化学分析的分析验证

获取原文
   

获取外文期刊封面封底 >>

       

摘要

PTEN loss is a promising prognostic and predictive biomarker in prostate cancer. Because it occurs most commonly via PTEN gene deletion, we developed a clinical-grade, automated, and inexpensive immunohistochemical assay to detect PTEN loss. We studied the sensitivity and specificity of PTEN immunohistochemistry relative to four-color fluorescence in situ hybridization (FISH) for detection of PTEN gene deletion in a multi-institutional cohort of 731 primary prostate tumors. Intact PTEN immunostaining was 91% specific for the absence of PTEN gene deletion (549/602 tumors with two copies of the PTEN gene by FISH showed intact expression of PTEN by immunohistochemistry) and 97% sensitive for the presence of homozygous PTEN gene deletion (absent PTEN protein expression by immunohistochemistry in 65/67 tumors with homozygous deletion). PTEN immunohistochemistry was 65% sensitive for the presence of hemizygous PTEN gene deletion, with protein loss in 40/62 hemizygous tumors. We reviewed the 53 cases where immunohistochemistry showed PTEN protein loss and FISH showed two intact copies of the PTEN gene. On re-review, there was ambiguous immunohistochemistry loss in 6% (3/53) and failure to analyze the same tumor area by both methods in 34% (18/53). Of the remaining discordant cases, 41% (13/32) revealed hemizygous (n=8) or homozygous (n=5) PTEN gene deletion that was focal in most cases (11/13). The remaining 19 cases had two copies of the PTEN gene detected by FISH, representing truly discordant cases. Our automated PTEN immunohistochemistry assay is a sensitive method for detection of homozygous PTEN gene deletions. Immunohistochemistry screening is particularly useful to identify cases with heterogeneous PTEN gene deletion in a subset of tumor glands. Mutations, small insertions, or deletions and/or epigenetic or microRNA-mediated mechanisms may lead to PTEN protein loss in tumors with normal or hemizygous PTEN gene copy number.
机译:PTEN丢失是前列腺癌有希望的预后和预测性生物标志物。因为它是最常见的通过PTEN基因缺失发生的现象,所以我们开发了一种临床级,自动化且廉价的免疫组织化学方法来检测PTEN的丢失。我们研究了PTEN免疫组织化学相对于四色荧光原位杂交(FISH)在多机构性731例原发性前列腺肿瘤中检测PTEN基因缺失的敏感性和特异性。完整的PTEN免疫染色对不存在PTEN基因缺失有91%的特异性(通过FISH检测到具有两个PTEN基因拷贝的549/602肿瘤通过免疫组织化学显示PTEN的完整表达),对纯合PTEN基因缺失的存在有97%的敏感性(不存在)通过免疫组织化学在纯合缺失的65/67肿瘤中表达PTEN蛋白)。 PTEN免疫组织化学对半合子PTEN基因缺失的敏感性为65%,在40/62个半合子肿瘤中蛋白质丢失。我们回顾了53例免疫组织化学显示PTEN蛋白缺失且FISH显示两个完整PTEN基因拷贝的病例。经复查,免疫组化丢失率为6%(3/53),而两种方法均无法分析同一肿瘤区域的比例为34%(18/53)。在其余不一致的病例中,有41%(13/32)揭示了大多数情况下集中的半合子(n = 8)或纯合子(n = 5)PTEN基因缺失(11/13)。其余的19例具有FISH检测到的PTEN基因的两个拷贝,代表了真正的不和谐病例。我们的自动PTEN免疫组织化学测定法是检测纯合PTEN基因缺失的灵敏方法。免疫组织化学筛选对鉴定肿瘤腺体中PTEN基因缺失的病例特别有用。突变,小的插入或缺失和/或表观遗传或microRNA介导的机制可能导致PTEN基因拷贝数正常或半合子的肿瘤中PTEN蛋白丢失。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号